132 related articles for article (PubMed ID: 38366182)
1. ASO Author Reflections: Is BRAF V600E Mutation Associated with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma?
Lai HF; Hang JF; Chen JY
Ann Surg Oncol; 2024 Jun; 31(6):3974-3975. PubMed ID: 38366182
[No Abstract] [Full Text] [Related]
2. Letter to the Editor: Comment on: "BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma".
Yu ST; Lei ST
Ann Surg Oncol; 2024 Jun; 31(6):3737-3738. PubMed ID: 38512604
[No Abstract] [Full Text] [Related]
3. Incidence of
Kure S; Ishino K; Kudo M; Wada R; Saito M; Nagaoka R; Sugitani I; Naito Z
J Int Med Res; 2019 Nov; 47(11):5560-5572. PubMed ID: 31533501
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the expression levels of BRAF
Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
[TBL] [Abstract][Full Text] [Related]
6. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].
Wang J; Liu LT; Cui D; He L; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264
[No Abstract] [Full Text] [Related]
7. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Ito Y; Yoshida H; Maruo R; Morita S; Takano T; Hirokawa M; Yabuta T; Fukushima M; Inoue H; Tomoda C; Kihara M; Uruno T; Higashiyama T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
Endocr J; 2009; 56(1):89-97. PubMed ID: 18840924
[TBL] [Abstract][Full Text] [Related]
10. An Animal Model Further Uncovers the Role of Mutant Braf
Koelsch B; Theurer S; Staniszewska M; Heupel J; Koch A; Mergener S; Walk F; Fischer C; Kutritz A; Schmid KW; Kindler-Röhrborn A
Am J Pathol; 2020 Mar; 190(3):702-710. PubMed ID: 31953036
[TBL] [Abstract][Full Text] [Related]
11. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma.
Collet JF; Lacave R; Hugonin S; Poulot V; Tassart M; Fajac A
Head Neck; 2016 Jul; 38(7):1017-21. PubMed ID: 26854757
[TBL] [Abstract][Full Text] [Related]
15. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between BRAF
Zhou B; Hei H; Li YQ; Zhang DY; Wang DQ; Qin JW
Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(14):1060-1063. PubMed ID: 37032157
[TBL] [Abstract][Full Text] [Related]
17. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
19. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF
Wang Z; Sun K; Jing C; Cao H; Ma R; Wu J
J Clin Lab Anal; 2019 Jul; 33(6):e22902. PubMed ID: 31021028
[TBL] [Abstract][Full Text] [Related]
20. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
